Physician profile
Derek Parkes
NPI 1205246790
$6,158.64
in general payments reported to CMS, 2019-2025
39 companies · $1,862 in 2025
The $1,862 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $145 · 2020: $196 · 2021: $559 · 2022: $844 · 2023: $1,205 · 2024: $1,348 · 2025: $1,862.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,414 · Education: $1.20.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,413.89 |
| Education | $1.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,191.31 | 2021-2025 | |
| Novo Nordisk INC | $714.18 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $659.65 | 2021-2025 | Caplyta |
| Lilly USA, LLC | $551.78 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Axsome Therapeutics, INC. | $414.51 | 2023-2025 | Auvelity |
| Pfizer INC. | $268.89 | 2020-2025 | |
| Vanda Pharmaceuticals INC. | $265.90 | 2025 | Fanapt |
| Corium, LLC | $234.47 | 2021-2025 | Azstarys |
| Ironshore Pharmaceuticals INC. | $208.05 | 2020-2024 | Jornay Pm |
| Supernus Pharmaceuticals, INC. | $187.42 | 2023-2024 | Qelbree, Qelbree |
| Allergan, INC. | $138.82 | 2019-2021 | |
| Collegium Pharmaceutical, INC. | $134.65 | 2025 | Jornay Pm |
| Biohaven Pharmaceutical Holding Company LTD. | $116.60 | 2022 | |
| Aimmune Therapeutics, INC. | $113.22 | 2024-2025 | Zenpep |
| Phathom Pharmaceuticals, INC. | $105.57 | 2024-2025 | Voquezna |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $90.50 | 2023-2025 | Farxiga, Airsupra, Breztri |
| Takeda Pharmaceuticals U.S.A., INC. | $85.96 | 2020-2023 | Gattex |
| Mylan Specialty L.P. | $74.64 | 2022-2024 | Yupelri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $73.73 | 2019-2025 | Jardiance |
| Nestle Healthcare Nutrition INC. | $71.47 | 2021-2023 | |
| Sanofi-Aventis U.S. LLC | $37.72 | 2020-2021 | |
| Abiomed | $37.15 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $34.45 | 2025 | Abilify Maintena, Rexulti |
| Dexcom, INC. | $31.79 | 2023-2025 | Dexcom G6 Transmitter |
| Amneal Pharmaceuticals LLC | $31.25 | 2020-2021 | |
| Tris Pharma INC | $29.01 | 2025 | Dyanavel Xr |
| Amgen INC. | $28.53 | 2025 | Repatha, Otezla |
| Novartis Pharmaceuticals Corporation | $25.34 | 2019 | |
| Biogen, INC. | $24.71 | 2023 | Spinraza |
| Eisai INC. | $23.71 | 2020-2021 | |
| Abbott Laboratories | $22.15 | 2025 | Freestyle Libre 3 |
| Exact Sciences Corporation | $21.65 | 2023 | Cologuard Collection Kit |
| Biohaven Pharmaceuticals, INC. | $19.69 | 2021 | |
| Lundbeck LLC | $16.47 | 2025 | Rexulti |
| Astellas Pharma US INC | $15.88 | 2023 | Veozah |
| Glaxosmithkline, LLC. | $15.61 | 2025 | Trelegy Ellipta |
| Bayer Healthcare Pharmaceuticals INC. | $14.94 | 2023 | |
| Idorsia Pharmaceuticals US INC | $14.48 | 2023 | Quviviq |
| Sanofi Pasteur INC. | $12.79 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Derek Parkes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.